Majed A. Refaai, M.D.

Contact Information

Phone Numbers

Office: (585) 276-3927

Fax: (585) 273-3003

A member of the University of Rochester Medical Faculty Group

An Accountable Health Partner

Accepting New Patients

Biography

Dr. Refaai's clinical service is in Transfusion Medicine with subspecialty involvement in laboratory coagulation/thrombosis testing.

Research

Dr. Refaai's recent studies have included: The in-vitro effect of ABO anti-bodies on platelet function; The correlation between cancer and tissue factor (TF) plasma concentrations and its role in developing DVT; The relationship between the circulating TF and the cancer tissue concentrations of TF in different types of mouse models; Beriplex phase IIIb drug study for bleeding patients with Warfarin overdose; Beriplex phase IIIb drug study for surgical patients who require a quick reversal of Warfarin; The effect of ABO non-identical blood products transfusion on platelet function (in-vivo); Platelet transfusion in patients with positive heparin-induced thrombocytopenia; Comparison of tissue factor pathway inhibitor (TFPI) concentration and activity in mononuclear cells from normal individuals versus patients with Paroxysmal Nocturnal Hemoglobinuria; Comparison of TFPI concentrations in normal mouse plasma and endothelial cells versus a diabetic mouse model; Analysis of fatty acid ethyl ester (FAEE) concentrations in binge drinking, chronic alcoholics, and postmortem biopsies.

Credentials

Specialties

Education

1993
MD | Aleppo University (Syria)

Post-doctoral Training & Residency

07/01/2006 - 06/30/2007
Fellowship in Blood Banking/Transfusion Medicine at University of Texas Southwestern Medical Center

06/30/2003 - 06/30/2006
Residency in Pathology at Washington University in St. Louis

04/01/1997 - 05/31/2003
Fellowship at Massachusetts General Hospital

04/01/1997 - 05/31/2003
Fellowship in Pathology at Massachusetts General Hospital

VIEW ALL

Patents

Patent Title: Systemic and Topical Application of Platelet Microparticles to Treat Bleeding in Trauma Patients
Patent #: 3265116
Issue Date: Jun 02, 2021
Country: Europe
Invented By: Majed A Refaai

Patent Title: Systemic and Topical Application of Platelet Microparticles to Treat Bleeding in Trauma Patients
Patent #: FR3265116
Issue Date: Jun 02, 2021
Country: France
Invented By: Majed A Refaai

Patent Title: Systemic and Topical Application of Platelet Microparticles to Treat Bleeding in Trauma Patients
Patent #: DE3265116
Issue Date: Jun 02, 2021
Country: Germany
Invented By: Majed A Refaai

Patent Title: Systemic and Topical Application of Platelet Microparticles to Treat Bleeding in Trauma Patients
Patent #: GB3265116
Issue Date: Jun 02, 2021
Country: United Kingdom
Invented By: Majed A Refaai

Patent Title: Systemic and Topical Application of Platelet Microparticles to Treat Bleeding in Trauma Patients
Patent #: ZL 201680012653.9
Issue Date: Mar 19, 2021
Country: China, People's Republic of
Invented By: Majed A Refaai

Patent Title: Systemic and Topical Application of Platelet Microparticles to Treat Bleeding in Trauma Patients
Patent #: 10,722,608
Issue Date: Jul 28, 2020
Country: United States
Invented By: Majed A Refaai

VIEW ALL

Publications

Journal Articles

3/5/2023
Gupta GK, Henrichs K, Nilsson K, Wagner S, Brown B, Masel D, Gestring ML, Vella MA, Refaai MA, Blumberg N. "Reduction of anti-A and anti-B isoagglutinin titers of group O whole blood units employing an ABO antibody immune adsorption column." Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.. 2023 Mar 5; :103686. Epub 2023 Mar 05.

1/2023
Spector H, McRae HL, Love T, Northam K, Refaai K, Rollins-Raval MA, Refaai MA. "Reduced Time to Procedure for Gastrointestinal Bleeding After Warfarin Reversal With Four-Factor Complex Concentrate as Compared to Plasma." Journal of clinical medicine research.. 2023 Jan; 15(1):51-57. Epub 2023 Jan 24.

12/27/2022
Hood C, Goldstein JN, Milling TJ, Refaai MA, Bajcic P, Goldstein B, Sarode R. "INR and vitamin K-dependent factor levels after vitamin K antagonist reversal with 4F-PCC or plasma." Blood advances.. 2022 Dec 27; Epub 2022 Dec 27.

VIEW ALL PUBLICATIONS